Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review
- PMID: 37649018
- PMCID: PMC10470127
- DOI: 10.1186/s12913-023-09512-6
Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: a qualitative systematic review
Abstract
Background: Preventable harm in healthcare is a growing public health challenge. In addition to the economic costs of safety failures, adverse drug events (ADE) may lead to complication or even death. Multidisciplinary care team involving a pharmacist appears to be an adequate response to prevention of adverse drug event. This qualitative systematic review aims to identify and describe multidisciplinary planned team-based care involving at least one pharmacist to limit or prevent adverse drug events in the adult patients.
Methods: To determine the type of interprofessional collaboration to prevent adverse drug event in which a pharmacist was involved, we conducted a qualitative systematic review of the literature of randomized controlled trials. Two independent reviewers screened trials in three databases: Medline, Web of Science, ScienceDirect. Prospective studies of at least three different health professionals' interventions, one of whom was a pharmacist in the last five years were included. Two reviewers performed data extraction and quality appraisal independently. We used TIDieR checklist to appraise articles quality.
Results: In total 803 citations were retrieved, 34 were analysed and 16 full-text articles were reviewed. Only 3 studies published an implementation evaluation. More than half of the interventions (62%) targeted elderly patients including 6 whom lived in nursing homes. Studies outcomes were heterogeneous, and we did not perform a statistical analysis of the impact of these interventions. Most teams are composed of a physician/pharmacist/nurse trio (94%; 100%; 88%). Half of the teams were composed of the primary care physician. Other professionals were included such as physical therapists (25%), social worker (19%), occupational therapists (12%), and community health educator (6%). Multidisciplinary medication review was the most common intervention and was generally structured in four steps: data collection and baseline assessment, appraisal report by health professionals, a multidisciplinary medication review meeting and a patient follow-up.
Conclusions: The most common multidisciplinary intervention to prevent ADE in the adult population is the multidisciplinary drug review meeting at least the physician/pharmacist/nurse trio. Interventions target mostly elderly people in nursing homes, although complex chronic patients could benefit from this type of assessment.
Trial registration: PROSPERO registration: CRD42022334685.
Keywords: Adverse drug event; Clinical pharmacist; Drug-related problems; Multidisciplinary team.
© 2023. BioMed Central Ltd., part of Springer Nature.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Community-based care for the management of type 2 diabetes: an evidence-based analysis.Ont Health Technol Assess Ser. 2009;9(23):1-40. Epub 2009 Oct 1. Ont Health Technol Assess Ser. 2009. PMID: 23074528 Free PMC article.
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes.Int J Clin Pharm. 2024 Oct;46(5):1163-1171. doi: 10.1007/s11096-024-01749-3. Epub 2024 Jul 5. Int J Clin Pharm. 2024. PMID: 38967733 Free PMC article.
-
Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis.Crit Care Med. 2019 Sep;47(9):1243-1250. doi: 10.1097/CCM.0000000000003830. Crit Care Med. 2019. PMID: 31135496
-
Effectiveness of pharmacist home visits for individuals at risk of medication-related problems: a systematic review and meta-analysis of randomised controlled trials.BMC Health Serv Res. 2020 Jan 15;20(1):39. doi: 10.1186/s12913-019-4728-3. BMC Health Serv Res. 2020. PMID: 31941489 Free PMC article.
Cited by
-
Impact of collaborative pharmaceutical care on older inpatients' medication safety: multicentre stepped-wedge cluster randomised trial (MEDREV Study).BMC Geriatr. 2025 Jul 11;25(1):516. doi: 10.1186/s12877-025-06122-1. BMC Geriatr. 2025. PMID: 40646458 Free PMC article. Clinical Trial.
-
Toxicity Derived from Interaction between Natural Compounds and Cancer Therapeutic Drugs Metabolized by CYP3A4: Lessons Learned from Two Clinical Case Reports.Int J Mol Sci. 2023 Nov 5;24(21):15976. doi: 10.3390/ijms242115976. Int J Mol Sci. 2023. PMID: 37958959 Free PMC article.
-
Cost-effectiveness in an interprofessional training ward within a university department for internal medicine: a monocentric open-label controlled study of the A-STAR Regensburg.Front Public Health. 2024 Aug 9;12:1340953. doi: 10.3389/fpubh.2024.1340953. eCollection 2024. Front Public Health. 2024. PMID: 39185108 Free PMC article.
-
Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cvMOBIUS2 registry.Am J Prev Cardiol. 2024 Dec 21;21:100921. doi: 10.1016/j.ajpc.2024.100921. eCollection 2025 Mar. Am J Prev Cardiol. 2024. PMID: 39876978 Free PMC article.
-
Therapeutic Education and Pharmacotherapeutic Follow-Up Protocol, a Useful Tool for the Improvement of Patients at Cardiovascular Risk in Community Pharmacies.J Cardiovasc Dev Dis. 2025 Feb 20;12(3):80. doi: 10.3390/jcdd12030080. J Cardiovasc Dev Dis. 2025. PMID: 40137078 Free PMC article.
References
-
- Garin N, Sole N, Lucas B, Matas L, Moras D, Rodrigo-Troyano A, Gras-Martin L, Fonts N. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11(1):883. 10.1038/s41598-020-80560-2. - PMC - PubMed
-
- Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995;274(1):29–34. - PubMed
-
- Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, Hallisey R, Ives J, Laird N, Laffel G, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274(1):35–43. - PubMed
-
- Michel P, Minodier C, Lathelize M, Motty-Monnereau C, Dmecq S, Chaleix M. Les évènements indésirables graves associés aux soins observés dans les établissements de santé. Dossiers Solidarité et santé n 17. Paris; 2010:8. https://drees.solidarites-sante.gouv.fr/sites/default/files/2020-10/dss1....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical